- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00096980
A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
June 19, 2013 updated by: Genentech, Inc.
An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment
This study is an open label, randomized, multicenter study designed to compare the efficacy of 12 weeks of subcutaneously administered efalizumab (monotherapy) with that of combination therapy (Efalizumab and a topical corticosteroid ointment) in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
The study will also evaluate the safety and tolerability of 30 months of continuous efalizumab treatment in those subjects who derive benefit from the initial 12 weeks of treatment.
Study Overview
Study Type
Interventional
Enrollment
300
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Diagnosis of plaque psoriasis for >=6 months
- A minimum Psoriasis Area and Severity Index (PASI) score of 12.0 at screening
- Plaque psoriasis covering >=10% of total Body Surface Area (BSA)
- In the opinion of the investigator, candidate for systemic therapy for psoriasis who has not been previously treated (naive to systemic treatment) or who has received prior systemic therapy for psoriasis (e.g., PUVA, cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil [MMF], thioguanine, hydroxyurea, sirolimus, azathioprine, 6 MP, etanercept)
- 18 to 70 years old
Exclusion Criteria:
- Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- Clinically significant psoriasis flare during the 3 months prior to enrollment
- Pregnancy or lactation
- History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- History of opportunistic infections (e.g., systemic fungal infections, parasites)
- Seropositivity for hepatitis B or C virus
- Seropositivity for human immunodeficiency virus (HIV)
- History of active tuberculosis (TB) or currently undergoing treatment for TB
- Presence or history of malignancy within the past 5 years, including lymphoproliferative disorders
- Diagnosis of hepatic cirrhosis, regardless of cause or severity
- Hospital admission for cardiovascular or pulmonary disease within the last year
- History of substance abuse within the last 5 years
- History of severe allergic or anaphylactic reactions to monoclonal antibodies or fusion proteins, which contain an immunoglobulin (Ig) Fc region (e.g., etanercept, LFA3TIP)
- History of severe allergic reactions to or intolerance of topical corticosteroid therapies
- Previous treatment with efalizumab
- History of treatment with lymphocyte-depleting monoclonal antibodies or immunoadhesion molecules (e.g., anti-CD4, CTLA4-Ig, LFA3TIP)
- WBC count <4000/uL or >14,000/uL
- Hepatic enzymes >=3 times the upper limit of normal
- Creatinine >=2 times the upper limit of normal
- Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug
- Any medical or other condition that, in the judgment of the investigator, would significantly interfere with the subject's ability to comply with the provisions of this protocol
- Topical therapy for psoriasis
- Systemic therapy for psoriasis
- Systemic immunosuppressive drugs
- Tanning beds, booths, or home UV light sources
- Live virus or bacteria vaccine
- Other vaccines or allergy desensitization injections
- Other experimental drugs or treatments
- Nonsteroidal anti inflammatory drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2001
Study Completion (Actual)
May 1, 2004
Study Registration Dates
First Submitted
November 17, 2004
First Submitted That Met QC Criteria
November 17, 2004
First Posted (Estimate)
November 18, 2004
Study Record Updates
Last Update Posted (Estimate)
June 21, 2013
Last Update Submitted That Met QC Criteria
June 19, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACD2243g
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Raptiva (efalizumab)
-
Oregon Health and Science UniversityCompletedDermatitis, Atopic
-
Genentech, Inc.Completed
-
Rockefeller UniversityGenentech, Inc.Completed
-
The Cleveland ClinicWithdrawnDiscoid Lupus Erthematosus of the ScalpUnited States
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Merck KGaA, Darmstadt, GermanyCompletedPsoriasis | Candidates for Systemic Therapy for PsoriasisSwitzerland
-
Northwestern UniversityGenentech, Inc.WithdrawnAlopecia Totalis
-
Genentech, Inc.Completed